File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells

TitleClinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells
Authors
Issue Date2014
PublisherMDPI AG, Basel, Switzerland.
Citation
Journal of Clinical Medicine, 2014, v. 3, p. 1105-1123 How to Cite?
AbstractThe lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human cell-based platform for the study of human hereditary cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac disorders for therapeutic studies have been increasingly highlighted. In this review, the standard procedures for generating patient-specific iPSCs and the latest commonly used cardiac differentiation protocols will be outlined. Furthermore, the progress and limitations of current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail.
Persistent Identifierhttp://hdl.handle.net/10722/211822

 

DC FieldValueLanguage
dc.contributor.authorNg, KM-
dc.contributor.authorLAW, CY-
dc.contributor.authorTse, HF-
dc.date.accessioned2015-07-21T02:12:02Z-
dc.date.available2015-07-21T02:12:02Z-
dc.date.issued2014-
dc.identifier.citationJournal of Clinical Medicine, 2014, v. 3, p. 1105-1123-
dc.identifier.urihttp://hdl.handle.net/10722/211822-
dc.description.abstractThe lack of appropriate human cardiomyocyte-based experimental platform has largely hindered the study of cardiac diseases and the development of therapeutic strategies. To date, somatic cells isolated from human subjects can be reprogramed into induced pluripotent stem cells (iPSCs) and subsequently differentiated into functional cardiomyocytes. This powerful reprogramming technology provides a novel in vitro human cell-based platform for the study of human hereditary cardiac disorders. The clinical potential of using iPSCs derived from patients with inherited cardiac disorders for therapeutic studies have been increasingly highlighted. In this review, the standard procedures for generating patient-specific iPSCs and the latest commonly used cardiac differentiation protocols will be outlined. Furthermore, the progress and limitations of current applications of iPSCs and iPSCs-derived cardiomyocytes in cell replacement therapy, disease modeling, drug-testing and toxicology studies will be discussed in detail.-
dc.languageeng-
dc.publisherMDPI AG, Basel, Switzerland.-
dc.relation.ispartofJournal of Clinical Medicine-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleClinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells-
dc.typeArticle-
dc.identifier.emailNg, KM: skykmng@hkucc.hku.hk-
dc.identifier.emailTse, HF: hftse@hkucc.hku.hk-
dc.identifier.authorityNg, KM=rp01670-
dc.identifier.authorityTse, HF=rp00428-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/jcm3041105-
dc.identifier.hkuros245133-
dc.identifier.volume3-
dc.identifier.spage1105-
dc.identifier.epage1123-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats